Gerresheimer (GXI) Given a €55.00 Price Target at Hauck & Aufhaeuser

Hauck & Aufhaeuser set a €55.00 ($65.48) price objective on Gerresheimer (ETR:GXI) in a report issued on Wednesday. The brokerage currently has a sell rating on the stock.

Other research analysts have also recently issued research reports about the stock. Goldman Sachs Group set a €69.50 ($82.74) price target on shares of Gerresheimer and gave the stock a neutral rating in a report on Wednesday, October 4th. JPMorgan Chase & Co. set a €99.40 ($118.33) price target on shares of Gerresheimer and gave the stock a buy rating in a report on Wednesday, October 11th. Independent Research set a €68.00 ($80.95) target price on Gerresheimer and gave the company a neutral rating in a research note on Wednesday, October 11th. Berenberg Bank set a €75.00 ($89.29) target price on Gerresheimer and gave the company a buy rating in a research note on Wednesday, October 11th. Finally, Kepler Capital Markets set a €65.00 ($77.38) target price on Gerresheimer and gave the company a sell rating in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of €70.62 ($84.07).

Shares of Gerresheimer (ETR:GXI) traded up €0.60 ($0.71) on Wednesday, hitting €71.55 ($85.18). The stock had a trading volume of 152,205 shares, compared to its average volume of 118,030. The firm has a market capitalization of $2,250.00 and a price-to-earnings ratio of 50.74. Gerresheimer has a twelve month low of €59.97 ($71.39) and a twelve month high of €78.25 ($93.15).

TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/gerresheimer-gxi-given-a-55-00-price-target-at-hauck-aufhaeuser.html.

About Gerresheimer

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply